Overview

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Ribavirin